Ascendia

  MARKET NEWS

 

Endogena Therapeutics Receives Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia & Weight Loss
Frontera Therapeutics Doses First Patient in a Clinical Trial of Gene Therapy for the Treatment of Wet AMD

  FEATURED EDITORIAL

  COMPANY PROFILE

Jubilant HollisterStier is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and sterile and non-sterile topicals and liquids. Our facilities in North America provide specialized manufacturing for the pharmaceutical and biopharmaceutical industries. We provide a full-range of support and services to streamline the manufacturing process such as on-site assistance from process qualifications through product release. With over 100 years of manufacturing expertise with a global reach, our team is committed to meeting your project’s milestones efficiently. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Stevanato Group Collaborates With Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma 

Stevanato Group Collaborates With Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma 

Leading drug containment provider to release a unique offering including both COP and COC pre-fillable syringes (PFS), adding to its existing glass PFS portfolio, providing customers with the broadest choice for PFS…. 

Revive Therapeutics Enters Research Collaboration Agreement With PharmaTher for Development of MDMA Transdermal Patch

Revive Therapeutics Enters Research Collaboration Agreement With PharmaTher for Development of MDMA Transdermal Patch

Revive Therapeutics Ltd. recently announced it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxy​methamphetamine (MDMA) using PharmaTher’s novel microneedle….

Purple Biotech Expands Pipeline of First-in-Class Therapeutics With Acquisition of Immunorizon & Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

Purple Biotech Expands Pipeline of First-in-Class Therapeutics With Acquisition of Immunorizon & Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

Purple Biotech Ltd. recently announced it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that….

Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation

Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation

First randomized controlled clinical trial to evaluate VX1-guided ablation compared to conventional anatomical ablation approaches to treat persistent atrial fibrillation….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 15 – Formulation Development
February 22 – ODT/Fast Dissolve